Disease-related mortality exceeds treatment-related mortality in patients with chronic myeloid leukemia on second-line or later therapy
详细信息 查看全文
- 作者：Edward Pearsona ; Edward.Pearson@baylorhealth.edu" class="auth_mail" title="E-mail the corresponding author ; Lisa McGarryb ; Lisa.McGarry@ariad.com" class="auth_mail" title="E-mail the corresponding author ; Smeet Galac ; sgala@mktxs.com" class="auth_mail" title="E-mail the corresponding author ; Christopher Niesetb ; Christopher.Nieset@ariad.com" class="auth_mail" title="E-mail the corresponding author ; Merena Nanavatyc ; mnanavaty@mktxs.com" class="auth_mail" title="E-mail the corresponding author ; Mkaya Mwamburic ; mmwamburi@mktxs.com" class="auth_mail" title="E-mail the corresponding author ; Yair Levya ; Moshe.Levy@BaylorHealth.edu" class="auth_mail" title="E-mail the corresponding author
- 关键词：Chronic myeloid leukemia ; Chronic phase ; Mortality ; Disease progression ; Treatment-related adverse events
- 刊名：Leukemia Research
- 出版年：2016
- 出版时间：April 2016
- 年：2016
- 卷：43
- 期：Complete
- 页码：1-8
- 全文大小：747 K
文摘
- class="listitem" id="list_lis0040">
- class="label">•
We compared death due to disease progression and treatment-related AEs in CP-CML.
- class="label">•
Relevant studies were identified by systematic literature review.
- class="label">•
Disease progression causes 10 times deaths as treatment-related AEs in CP-CML.
- class="label">•
Excessive deaths in CP-CML on later line therapy as compared to US census estimates.
- class="label">•
Benefits of effective treatment outweigh risks of treatment-related mortality.